Cellectis to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), will present at several upcoming investor conferences. Webcast information when available will be posted in the Investor Relations section of the Company’s website at https://www.cellectis.com/en/investors/events-and-webcasts/
Citi Annual BioPharma Conference September 9, 2020 from 3:20 PM to 4:05 PM EDT
André Choulika, Chairman & CEO, to participate in a panel on Innovation in Cell Therapy.
Wells Fargo Healthcare Conference Boston September 10, 2020 from 8:00 AM to 8:30 AM EDT
André Choulika; Carrie Brownstein, CMO; Simon Harnest, VP, Corporate Strategy & Finance to provide a company presentation.
Baird’s 2020 Global Healthcare Conference September 10, 2020 at 3:10 PM EDT
Simon Harnest to participate in a firechat and a live Q&A.
Bank of America Healthcare Conference London September 17, 2020 from 4:55 AM to 5:45 AM EDT
André Choulika to provide a company presentation.
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).
Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.
TALEN® is a registered trademark owned by Cellectis.
For further information, please contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, email@example.com
Fluicell mottar sin andra köporder från Oblique Therapeutics AB avseende Dynaflow® Resolve-system
Fluicell AB (publ.) (“Fluicell” eller ”Bolaget”) meddelar härmed att Bolaget mottagit en köporder på ett Dynaflow® Resolve-system från det svenska biotechbolaget Oblique Therapeutics AB (”Oblique Therapeutics”). Detta är Fluicells andra försäljning under 2020 av ett Dynaflow® Resolve-system ti...
First day of trading with warrants of series TO4
As previously communicated, Cyxone AB (publ) (“Cyxone” or the “Company”) has resolved to allocate one (1) warrant of series TO4 to the Company’s existing shareholders for every twenty-eight (28) shares owned on the record date of November 19, 2020. The Warrants will, to some extent, compensate the c...
Första dag för handel i teckningsoptioner av serie TO4
Som tidigare kommunicerats har Cyxone AB (publ) (“Cyxone” eller “Bolaget”) beslutat att tilldela en (1) teckningsoption av serie TO4 till Bolagets befintliga aktieägare för varje tjugoåtta (28) ägda aktier per avstämningsdagen den 19 november 2020. Teckningsoptionerna kommer att, till viss del, komp...
Bulletin from the Extraordinary General Meeting in Magle Chemoswed on 27 November 2020
At the Extraordinary General Meeting in Magle Chemoswed Holding AB (publ) held on 27 November 2020, it was resolved to approve the Board’s resolution on a new share issue with pre-emptive rights for the shareholders of SEK 20 million, before transaction costs. Through the rights issue, not more than...